Genmab A (GMAB) Gross Margin (2018 - 2026)
Genmab A's (GMAB) quarterly Gross Margin came in at 92.73% in Q2 2026, down 124.0% on a YoY basis from 386.36% in Q2 2025, and little changed quarter-over-quarter from 92.75% in Q1 2026.
Powered by 
Analysis
Genmab A (GMAB) Gross Margin (2018 - 2026) Analysis & Trends
Genmab A (GMAB) has reported Gross Margin for 8 consecutive years, with 92.73% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Gross Margin fell 124.0% year-over-year to 92.73%; the trailing twelve-month figure through Jun 2026 stood at 93.63% (down 147.0% YoY), and the FY2025 full-year result was 93.6%, down 182.0% from the prior year.
- Gross Margin was little changed at 92.73% in Q2 2026 per GMAB's latest filing, from 92.75% in the prior quarter.
- Across five years, Gross Margin topped out at 100.35% in Q4 2023 and bottomed at 92.73% in Q2 2026.
- Historically, Gross Margin has averaged 95.31% across 4 years, with a median of 94.82% in 2024.
- The sharpest annual moves came in 2024 and 2026: Gross Margin sank 221 bps in 2024, then sank 124 bps in 2026.
- Over 4 years, Gross Margin stood at 100.35% in 2023, then dropped by 5 bps to 95.68% in 2024, then dropped by 2 bps to 94.1% in 2025, then decreased by 1 bps to 92.73% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 92.73%, 92.75%, and 94.1% for Q2 2026, Q1 2026, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 72.04% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 79.76% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 85.33% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 91.59% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 35.86% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 90.43% |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 76.90% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 71.60% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | 80.31% |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn | 92.73% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 92.73% |
| Mar 31, 2026 | 92.75% |
| Sep 30, 2025 | 94.10% |
| Jun 30, 2025 | 93.96% |
| Mar 31, 2025 | 94.13% |
| Sep 30, 2024 | 95.68% |
| Jun 30, 2024 | 96.02% |
| Mar 31, 2024 | 95.52% |
| Dec 31, 2023 | 100.35% |
| Sep 30, 2023 | 97.89% |
| Dec 31, 2021 | -253.36% |
| Sep 30, 2021 | 99.96% |
| Dec 31, 2020 | 99.89% |
| Dec 31, 2019 | -657,859.62% |
| Dec 31, 2018 | 100.00% |